newsfilter
← Latest News
Business Wire·

Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial

Patient screening underway in the United Kingdom in trial to assess oral product candidate's potential to address Long COVID fatigue and muscle weakness Top-line data readout anticipated by mid-2022 Axcella Therapeutics (NASDAQ:AXLA), a clini